A phase II trial with monoclonal antibody CG250 in advanced renal cell carcinoma.

被引：0
|
作者：
Varga, Z
Hegele, A
Hofmann, R
De Mulder, PD
Kruit, W
Warnaar, S
Mala, C
Ullrich, S
Huber, C
Lamers, C
Beck, J
机构：
来源：
JOURNAL OF UROLOGY | 2002年 / 167卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：192 / 193
页数：2
相关论文
共 50 条
  • [1] Phase I/II radioimmunotherapy with I-131 labeled chimeric monoclonal antibody cG250 in patients with metastasized renal cell carcinoma.
    Steffens, MG
    Boerman, OC
    Oosterwijk, E
    Oyen, WJG
    De Mulder, PHM
    Witjes, JA
    Oosterhof, GON
    Debruyne, FMJ
    Corstens, FHM
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (05) : 247P - 247P
  • [2] Radioimmunotherapy of advanced renal cell carcinoma patients with Lutetium-177 labeled monoclonal antibody cG250
    Oosterwijk, E.
    Stillebroer, A.
    Boerman, O. C.
    De Weijer, K. J. M.
    Hendrickx, B. W.
    Oyen, W. J. G.
    Mulders, P. F. A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 238 - 238
  • [3] Radioimmunotherapy with lutetium-177 labeled monoclonal antibody cG250 in patients with advanced renal cell carcinoma
    Stillebroer, A. B.
    Oosterwijk, E.
    Mulders, P. F. A.
    Oyen, W. J. G.
    Boerman, O. C.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2008, 23 (04) : 523 - 524
  • [4] Radioimmunotherapy of advanced renal cell carcinoma patients with Lutetium-177 labeled monoclonal antibody cG250
    Stillebroer, A. B.
    Hendrickx, B. W.
    Oosterwijk, E.
    de Weijer, K.
    Steffens, M. G.
    Boerman, O. C.
    Mulders, P. F. A.
    Oyen, W. J. G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S169 - S169
  • [5] A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients
    M. Siebels
    K. Rohrmann
    R. Oberneder
    M. Stahler
    N. Haseke
    J. Beck
    R. Hofmann
    M. Kindler
    P. Kloepfer
    C. Stief
    World Journal of Urology, 2011, 29 : 121 - 126
  • [6] A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREXA®) and interferon-alpha-2a in metastatic renal cell carcinoma patients
    Siebels, M.
    Rohrmann, K.
    Oberneder, R.
    Stahler, M.
    Haseke, N.
    Beck, J.
    Hofmann, R.
    Kindler, M.
    Kloepfer, P.
    Stief, C.
    WORLD JOURNAL OF UROLOGY, 2011, 29 (01) : 121 - 126
  • [7] A Prospective Open-label Single-Arm Phase II Study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients
    Varga, Z
    de Mulder, P
    Kruit, W
    Hegele, A
    Hofmann, R
    Lamers, C
    Warnaar, S
    Mala, C
    Ullrich, S
    Mulders, P
    FOLIA BIOLOGICA, 2003, 49 (02) : 74 - 77
  • [8] OPTICAL IMAGING OF RENAL CELL CARCINOMA USING THE ANTI-CAIX MONOCLONAL ANTIBODY CG250
    Stillebroer, A. B.
    Oosterwijk, E.
    Franssen, G. M.
    Oyen, W. J. G.
    Boerman, O. C.
    Mulders, P. F. A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 105 - 105
  • [9] Results of a phase I/II study with monoclonal antibody CG250 in combination with IFN α-2A in metastatic renal cell carcinoma patients.
    Bevan, P
    Mala, C
    Kindler, M
    Siebels, M
    Oberneder, R
    Beck, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 408S - 408S
  • [10] A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
    Bleumer, I
    Knuth, A
    Oosterwijk, E
    Hofmann, R
    Varga, Z
    Lamers, C
    Kruit, W
    Melchior, S
    Mala, C
    Ullrich, S
    De Mulder, P
    Mulders, PFA
    Becks, J
    BRITISH JOURNAL OF CANCER, 2004, 90 (05) : 985 - 990
12345